ST-segment myocardial infarction (STEMI) causes significant morbidity and mortality, with infarct size being the primary predictor of clinical outcome. Given imaging evidence that early IV metoprolol ...
Advanced CKD was linked to a higher likelihood of both fatal and non-fatal adverse outcomes after acute myocardial infarction treatment. Patients with advanced chronic kidney disease (ACKD) with acute ...
New evidence reveals adult human hearts can regrow muscle cells after myocardial infarction, opening new possibilities for ...
The findings confirm the results of the CNIC-led REBOOT clinical trial and consolidate a paradigm shift in infarction treatment. A major analysis led by the Centro Nacional de Investigaciones ...
Empagliflozin stabilizes kidney function and reduces heart failure risk post-myocardial infarction, with eGFR remaining stable over 24 months. The EMPACT-MI trial confirmed empagliflozin's safety when ...
For patients who present with essential hypertension and further symptoms of possible heart failure, it is important for physicians to consider and treat the patient's underlying disease. A ...
ESTERO, FLORIDA / ACCESS Newswire / September 3, 2025 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) (“Aspire” or the “Company”), developer of a multi-faceted patent-pending drug delivery technology, ...
MULHOUSE, France, and SUNNYVALE, Calif., July 08, 2024 (GLOBE NEWSWIRE) -- CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and BioCardia, Inc.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results